Aclaris Therapeutics, Inc.
LSE: 0H8T.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Neal S. Walker
- Employees
- 61
- Headquarters
- Wayne, United States
- IPO year
- 2018
- Market cap
- $598.9M
- Website
- https://www.aclaristx.com
Loading 0H8T…
Loading profile data…Frequently asked questions about 0H8T
What does Aclaris Therapeutics, Inc. (0H8T.L) do?
Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant...
Where does 0H8T.L trade?
Aclaris Therapeutics, Inc. (0H8T.L) trades on the London Stock Exchange.
What sector is 0H8T.L in?
Aclaris Therapeutics, Inc. (0H8T.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Aclaris Therapeutics, Inc.?
Neal S. Walker is the chief executive officer of Aclaris Therapeutics, Inc. (0H8T.L).
Where is Aclaris Therapeutics, Inc. headquartered?
Aclaris Therapeutics, Inc. is headquartered in United States.
Does 0H8T.L pay a dividend?
Aclaris Therapeutics, Inc. (0H8T.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0H8T.L go public?
Aclaris Therapeutics, Inc. (0H8T.L) completed its initial public offering in 2018.